The spinout, known as Celea Therapeutics, will advance what’s designed to be an improved version of the drug pirfenidone for ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its ...